新型抗真菌化合物F901318对澳大利亚瓶霉属和卷枝霉属真菌的体外活性
In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi.
作者信息
Biswas Chayanika, Law Derek, Birch Michael, Halliday Catriona, Sorrell Tania C, Rex John, Slavin Monica, Chen Sharon C-A
机构信息
Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital, Sydney, Australia.
F2G Limited, Manchester, UK.
出版信息
Med Mycol. 2018 Nov 1;56(8):1050-1054. doi: 10.1093/mmy/myx161.
We determined the in vitro activity of the novel orotomide antifungal, F901318, against 30 Lomentospora prolificans, 20 Scedosporium apiospermum, 7 S. aurantiacum, and 3 S. boydii, isolates in comparison with standard antifungals. Against L. prolificans, F901318 was the most potent compound (MIC90 0.25 μg/ml); the geometric mean MIC (0.26 μg/ml) was significantly lower (23-80-fold) than those of itraconazole, voriconazole, posaconazole, and isavuconazole (all P < .001), and amphotericin B (P < .05). F901318 also had good activity against S. apiospermum, S. aurantiacum, and S. boydii, comparable to that of voriconazole and posaconazole but was more active than isavuconazole for all three species.
我们测定了新型口酰胺类抗真菌药F901318对30株多育镰刀菌、20株尖端赛多孢子菌、7株桔黄赛多孢子菌和3株博伊德赛多孢子菌分离株的体外活性，并与标准抗真菌药进行比较。对于多育镰刀菌，F901318是最有效的化合物（MIC90为0.25μg/ml）；几何平均MIC（0.26μg/ml）显著低于伊曲康唑、伏立康唑、泊沙康唑和艾沙康唑（均P<0.001）以及两性霉素B（P<0.05）（低23至80倍）。F901318对尖端赛多孢子菌、桔黄赛多孢子菌和博伊德赛多孢子菌也有良好活性，与伏立康唑和泊沙康唑相当，但对所有这三个菌种都比艾沙康唑更具活性。
Zotero 插件